

1102865-0047

IN THE SPECIFICATION:

1. On page 5, at the end of line 11, please insert the following statement:

1A An embodiment of the invention provides a synthetic immunogenic fusion peptide selected from the group consisting of one or more than one peptide defined by SEQ ID NO: 10 and SEQ ID NO: 11.

2. In Example I, last paragraph on page 6, (line 16-19), please replace the following amended sentence.

AZ Promiscuous Th-epitope moieties from measles virus protein F (MSF) (sequence 288-302 aa, SEQ ID NO: 8), tetanus toxoid (TT) (sequence 947-957 aa, SEQ ID NO: 4, or sequence 830-844 aa, SEQ ID NO: 2) and malaria Plasmodium falciparum CSP protein (sequence 378-398 aa, SEQ ID NO: 3) are used in these constructs.